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BACKGROUND: The PI3K/AKT/mTOR pathway alterations have been shown to play significant roles in the development,
progression, andmetastatic spreadofbreast cancer. Furthermore, theyhavebeen implicated in theprocessofdrug resistance,
especiallyendocrinal therapies. In thisstudy,weaimedtodefine thecorrelationbetween thePI3Kmutationsand theexpression
of the phosphorylated forms of different downstream molecules in women with estrogen receptor (ER)–positive, human
epidermal growth factor receptor2–negative (luminal) early breast cancer treatedatCairouniversity hospitals.METHODS:Next-
generation sequencingwas used to detectmutations in the PIK3CAhotspots (in exons 9 and 20). Immunohistochemistrywas
performed on tissuemicroarray blocks prepared from samples of 35 Egyptian luminal breast cancer patients in the pathology
departmentofCentre LéonBérard (CLB). The intensity and thepercentageof stained tumor cellswere integrated todefinehigh
versus low biomarker expression. The cytoplasmic and nuclear stainingswere graded separately. Patientswere followed for a
medianof4.7years (2.1 to6.9years).CorrelationwasdonebetweenPI3Kmutationsand the immunohistochemistryexpression
of pAKT, LKB1, p4EBP1, and pS6 ribosomal protein (pS6RP)with the clinicopathologic features and disease free survival (DFS)
of the patients.RESULTS:Median age at diagnosis was 51.3 years (range, 25 to 82 years). Tumors were larger than 20mm in
79.2% of the cases, whereas 57.9% had axillary lymph node deposits. Only 12.3% of the patients had SBR grade I tumors,
50.8% had grade II, and 36.8% had grade III. ERs were negative in 6 patients (17%) after pathology review. Thirty-two cases
were assessable for LKB1 and pAKT, 33 for p4EBP1 and pS6RP, and 24 for PI3Kmutations. Nuclear LKB1, cytoplasmic LKB1,
nuclear pAKT, cytoplasmic pAKT, nuclear p4EBP1, and cytoplasmic pS6RP expression was high in 65.6%, 62.5%, 62.5%,
68.8%, 42.4%, and 57.6%, respectively. PIK3CAmutations were found in 7 patients (29.2%). PI3Kmutations were correlated
withnuclear localizationof pAKT (i.e., decreasedcytoplasmicpAKT,P=.04; and increasednuclear pAKT,P=.10). Therewasa
tendency toward an inverse correlation between PI3Kmutations and the expression of pS6RP (P= .10) and p4EBP1 (P= .19).
Nuclear LKB1 expressionwas amarker of good prognosis. It was associatedwith smaller tumors (P= .05),more ER (P= .08)
andprogesteron receptor (PgR)positivity (P=.002). In theKaplanMeier (KM)model,patientswithhighnuclearLKB1had longer
DFS (hazard ratio = 0.36; 95% confidence interval, 0.15-1.10; P= .08). Nuclear pAKT high expression also carried a tendency
toward longer DFS (hazard ratio = 0.51; 95% confidence interval, 0.11-1.16; P= .13). The expression of p4EBP1, pS6RP, and
the PI3K mutational status did not show any prognostic significance in our cohort. CONCLUSION: Among the studied
biomarkers, onlynuclear expressionofLKB1andpAKT tended topredict better survival inbreast cancerpatients. PI3Kmutation
was correlated with the expression of nuclear pAKT but not pS6RP or p4EBP1.
Translational Oncology (2016) 9, 114–123© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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The PI3K/AKT/mTOR pathway is a key regulator of cell growth,
proliferation, and survival in normal as well as cancer cells. Deregulation of
PI3K signalingmay occur throughmutation in PIK3CA gene (which codes
for ligand-independent PI3K catalytic subunit), overexpression of upstream
receptors (such as EGFR, Her2, and IGF-R1), or loss of function of its
negative regulators (PTEN, TSC, and LKB1). LKB1 (also known as
serine-threonine kinase 11 or STK11) has been described to negatively
control mTOR signaling derived by the intracellular energy sensing via
activation of TSC 1/2. Activated PI3K is responsible for AKT
phosphorylationwith its subsequent translocation to the plasmamembrane,
where it can activate many downstream signaling networks [1–3].
Of particular interest among the Akt targets is its downstream
effect on mTOR kinase. The later integrates signals from nutrients,
energy status, and extracellular growth factors to regulate many
cellular processes, including cell cycle progression, angiogenesis,
ribosome biogenesis, and metabolism. Most of the mTOR-mediated
cellular processes are executed via phosphorylation of its two
downstream effectors: 4E-BP1 and S6 kinase [2]. It is of note that
ongoing studies are testing specific inhibitors of S6 kinases such as
saquinavir-NO in vitro and in vivo for treatment of different cancers
and autoimmune conditions with promising results [4,5].
The importance of abnormal PI3K/AKT/mTOR signaling has
been demonstrated to occur in several diseases including different
cancers, HIV, and HCV infections in addition to autoimmunity
[6,7]. This has highlighted the relevance of this pathway as a possible
therapeutic target for these diseases. In particular, several clinical trials
have been initiated to address the role of mTOR inhibitors, whether
alone or in combination across different tumor types [8–10].
In breast cancer, extensive preclinical evidence has implicated
PI3K/AKT/mTOR pathway deregulation in acquired resistance to
endocrine therapy, which gave a molecular rational to the combined
inhibition of estrogen receptor (ER) and mTOR pathways in these
patients [11]. In two randomized clinical trials (TAMRAD and
BOLERO2), hormone receptor (HR)–positive/human epidermal
growth factor receptor 2 (HER2)–negative metastatic breast cancer
patients treated with of the mTOR inhibitor everolimus in
combination with endocrinal therapy exhibited a significant increase
in progression-free survival (PFS) and clinical benefit compared with
patients treated with endocrinal therapy alone [12,13].
Importantly, future treatment optimization of these drugs will
certainly require assessing multiple biomarkers related to the activation
state of the different components of the PI3K/AKT/m-TOR pathway
with validation of these markers on different cohorts of patients.
In the current study, we aimed to assess the prevalance of PI3K/
AKT/m-TOR pathway effectors dysregulation, namely, pS6 ribo-
somal protein (pS6RP), LKB1, pAKT, and p4E-BP1 expression and
PIK3CA mutations, in a group of Egyptian women with early HR+/
HER2− breast cancer. Biomarker analysis was done in collaboration
with the pathology laboratory in Centre Léon Bérard (CLB), which
has served as a central laboratory for the TAMRAD study.
Furthermore, we tried to correlate these biomarkers with the known
clinicopathologic factors and relapse events of the studied patients.
Patients and Methods
Patient Population
Between January 2007 and December 2011, we screened 400
consecutive female patients with operable primary breast cancer whoment at the Department of Clinical Oncology, Cairo University. For
eligibility, female patients older than 18 years at diagnosis should have
a documented pathological proof of primary breast cancer and should
have had their primary curative surgery (either modified radical
mastectomy or breast saving surgery) and all adjuvant treatment and
follow-up at our institution. The patients should have luminal breast
cancer subtype, positive for ER +/− PgR (N10%) and negative for
HER2 overexpression. All patients received adjuvant endocrine
therapy, either tamoxifen if premenopausal or aromatase inhibitors if
postmenopausal, according to the local guidelines.
Among the screened 400 patients, 186 patients were found eligible
(as per the previously mentioned criteria) for the study, and 214 cases
were excluded. Paraffin blocks of tumor tissue were only available for
58 patients. Among those, not enough malignant tissue could be
found in the paraffin blocks of 23 cases, and only 35 cases contained
enough tumor tissue for tissue microarray (TMA) construction and
biomarker testing in the pathology laboratory of CLB (Figure 1).
Among those 35 samples (and because of further tissue loss during
sectioning of the TMA block), 32 cases were assessable for pAKT and
LKB1, and 33 cases were assessable for pS6RP and p4E-BP1. PI3K
hotspot mutations were assessed in 29 patients (see later). A flowchart
of the whole population and subsets tested for different biomarkers is
shown in Figure 2. The database was locked to further events on 30
September 2014, and all patients who were alive and/or disease free
on that date were censored.
The study population was followed up for a median of 36 months
(range, 15.6 to 74 months).
Patients underwent either modified radical mastectomy or
breast-conserving surgery. Lymph node (LN) invasion was assessed
by axillary level I and II LN dissection, and the number of LNs
harboring metastasis was determined based on histologic examina-
tion. No cases had sentinel LN sampling. Tumor size was defined as
the maximum tumor diameter measured on the tumor specimens at
the time of surgery. ERs and progesterone receptors (PgRs) were
detected by immunohistochemistry (IHC), and tumors were
considered positive if they have nuclear staining in 10% or more of
the tumor cells (or score of 3 or more by Allred's method). HER2
expression was determined using IHC, and tumors were considered
positive if they had 3+ staining (intense staining in 10% or more
cancer cells) by IHC or 2+ staining with HER2 amplification
detected by fluorescence in situ hybridization.
The data exported from the patients' files for analysis included age,
histologic subtype, maximum tumor size, number of LNs involved,
Scarf Bloom Richardson (SBR) grade, ER, PgR expression, HER2
overexpression, date of diagnosis, date of relapse, and date of death or
last follow-up. Tumor samples and clinical data were obtained under
Institutional Review Board approval. This study is reported according
to the “Reporting Recommendations for Tumor Marker Prognostic
Studies” criteria [14].
Immunohistochemical Analysis
A 4-μm–thick section was obtained from each of the selected
paraffin blocks chosen for the study. Two regions containing the
highest percentage of malignant cells were selected, one for the TMA
and the other for DNA extraction and PIK3CA sequencing. Breast
tumor cores were inserted as triplicates (three cores for each patient)
using a 600-μm needle in one TMA block. The block containing
invasive carcinomas was sectioned at a thickness of 4 μm. After
Figure 1. Different molecules involved in the mTOR activation cascade. Studied molecules (marked with green rectangles) are PI3K
mutations, pAKT, LKB1, pS6 ribosomal protein, and p4E-BP. Adapted with modifications from Azim et al [3].
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Figure 2. A flowchart of the whole population and subsets tested
for different biomarkers.
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blocked by incubating the slides in 5% hydrogen peroxide in sterile
water. Heat-induced antigen retrieval was performed for all the
antibodies in CC1 standard on Discovery automate (Roche
Diagnostic, Meylan, France) for 60 minutes.
The slides were then incubated inDiscovery automate for 60minutes
with the following antibodies diluted in Dako Real Antibody Diluent
(Dako, Trappes, France): anti-LKB1 (rabbit polyclonal antibody from
Abcam [Cambridge, UK]) at 1/50, anti-pAKT (rabbit monoclonal
antibody from Abcam) at 1/25, anti-pS6RP (rabbit monoclonal
antibody 91B2 from Cell Signaling [Danvers, MA]) at 1/100, and
anti-p4EBP1 antibody (rabbit polyclonal from Cell Signaling) at 1/200.
Primary bound antibodies were revealed using Rb OmniMap Kit
(Roche) for LKB1, pS6RP, and p4EBP1 antibodies or RbUltraMap Kit
(Roche) for pAKT antibody and then DAB ChromoMap Kit (Roche).
Sections were counterstained with hematoxylin and Bluing (Roche).
Blinded to the clinical data, the biomarkers’ expression was evaluated
by two observers who assessed both the percentage and the intensity of
nuclear and cytoplasmic staining for LKB1 and pAKT and of nuclear
staining for pS6RP and p4EBP1 in the infiltrative carcinomatous cells
only. For scoring purposes, the highest intensity of staining in malignant
cells was classified into four levels (0: no staining, 1: weak staining, 2:
moderate staining, 3: strong staining), and the percentage of stained cells
was also classified into four levels (0: no stained cells, 1: staining in less
than one third of themalignant cells, 2: staining in one to two thirds of the
malignant cells, 3: staining inmore than two thirds of themalignant cells).
Then both intensity and the percentage scores were added to conclude a
single score (from 0 to 6) in a manner similar to the Allred score for ER
and PR staining [15]. In cases where both a nuclear staining and
cytoplasmic staining were observed, then two different scores were
obtained independently, one for the nuclear and one for the cytoplasmic
staining.
A B
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Figure 3. Representative images of microscopic pictures showing
tumor cellswith high expression of nuclear LKB1 (A), cytoplasmic LKB1
(B) and lowexpression of LKB1 (C). Tumor cellswith high expression of
nuclear pAKT (D), cytoplasmicpAKT (E), and lowexpressionof pAKT (F).
Tumor cellswith high (G) and low (H) expressionof p4E-BP1, and tumor
cells with high (I) and low (J) expression of pS6RP.
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considered to have low expression of nuclear or cytoplasmic LKB1 if
they had a score of 0 and high expression if they had a score of 1 or
more. For nuclear or cytoplasmic pAKT and for pS6RP, expression
was considered low with a score of 0 to 1 and high with a score of 2 or
more. For p4E-BP1, expression was considered low with a score of 0
to 2 and high with a score of 3 or more.
Gene Sequencing
Paraffin blocks were scraped in a selected area containing more
than 50% of tumor cells, and DNA was extracted. Twenty
nanograms of DNA was used for the Ion Torrent library preparation
of exons 9 and 20 of PIK3CA gene (NM_006218.2) following the
manufacturer’s protocol for the Ion AmpliSeq Libray Kit 2.0 (Life
Technologies). The size distribution of the DNA amplicons was
analyzed on the 2200 TapeSation (Agilent) using the high-sensitivity
kit (Agilent). Template preparation, emulsion PCR, and ion sphereparticle enrichment was performed using the One Touch 2 kit (Life
Technologies) according to manufacturer’s instructions. The ion
sphere particles were loaded onto a 318 chip (Life Technologies) and
sequenced using an Ion PGM 200 v2 sequencing kit (Life
Technologies) on the Ion Torrent PGM for 500 cycles. The raw
signal data were analyzed using NextGENe Software Suite v3.4.2
(Softgenetics; NGS). The pipeline includes quality score assignment,
alignment to human genome 19 reference, mapping quality QC,
coverage analysis, and variant calling.
Statistical Analysis
The correlation between LKB1, pAKT, pS6RP, and p4EBP1
expression and clinicopathologic characteristics was determined using
Fisher’s exact test for categorical variables and Student's t test for
numerical variables. Relapse-free survival (RFS) was defined as the
time from the date of diagnosis of breast cancer to the date of any
cancer recurrence (local, distant, or contralateral) or death. Overall
survival was defined as the time from the date of diagnosis of breast
cancer to the date of death.
The database was locked at the same time point for all patients
corresponding to 30 August 2014, and no events were recorded after
that point.
Survival curves and mean and median RFS (if reached), in addition
to 60-month RFS and overall survival rates (with 95% confidence
intervals [CIs]), were derived from Kaplan-Meier estimates, and the
curves were compared using log-rank test [16]. Hazard ratios and
95% CIs were calculated using Cox regression model [17]. All
statistical tests were two-sided, and in view of the small size of our
sample and the exploratory nature of our analysis, the P value was
considered statistically significant if less than 0.1. The statistical
analyses were performed using SPSS 17.0 statistics package (SPSS
Inc., Chicago, IL).
Results
Clinicopathological Characteristics
For the 58 patients eligible for the first stage of the study, the
median follow-up interval was 4.7 years (range, 2.1 to 6.9 years).
Median age at diagnosis was 51.3 years (range, 25 to 82 years). The
majority of the patients (79.2%) had tumors larger than 2 cm in
maximum dimension, and 57.9% had axillary LN metastasis. Twenty
patients (35.1%) had four or more positive LN. Invasion by a
malignant deposit less than 2 mm (N1mic) was not considered
positive in this analysis. Most of the patients (81%) had invasive
ductal carcinomas or mixed subtypes. Only 12.3% of the patients had
SBR grade I tumors, 50.9% had grade II tumors, and 36.8% had
grade III tumors.
Estrogen receptor was expressed in all the patient population at the
central laboratory in Egypt, whereas at CLB laboratory, 6 patients
(10.5%)were found to lack expression of ER. Progesterone receptor was
expressed in 77.6% of the patients' samples. HER2 was found to be
expressed in four patients (10%) after revision at CLB laboratory. As a
result of absence of validated and standardized technique for Ki-67
testing at the time of starting our work, it was not tested in this study.
Forty-one patients (70.7%) received adjuvant chemotherapy, 15 of
them received anthracyclin-based therapy, 23 of them received
sequential anthracyclins and taxanes, whereas 3 patients had a
taxane-only chemotherapy. Fifty-seven (98.3%) patients received
adjuvant hormonal treatment, 33 of them received tamoxifen only,
whereas 24 patients had sequential tamoxifen and aromatase
Table 1. Biomarker Distribution in the Final Patient Cohort (58 Patients)
Biomarker Number Percent
PI3K hotspot mutations Wild 17 70.2%
Mutant 7 29.2%
Missing 34
Nuclear LKB1 Low 11 34.4%
High 21 65.6%
Missing 26
Cytoplasmic LKB1 Low 12 37.5%
High 20 62.5%
Missing 26
Nuclear pAKT Low 12 37.5%
High 20 62.5%
Missing 26
Cytoplasmic pAKT Low 10 31.2%
High 22 68.8%
Missing 26
P4EBP1 Low 19 57.6%
High 14 42.4%
Missing 25
pS6RP Low 14 42.2%
High 19 57.6%
Missing 25
Table 2. Correlation between PI3K Hotspot Mutations (by NGS) and Biomarker Distribution (by
IHC)
Marker PI3K Wild No. (%) PI3K Mutant No. (%) P Value
Nuclear LKB1 Low 6 (40%) 3 (42.9%) .89
High 9 (60%) 4 (57.1%)
Cytopl. LKB1 Low 6 (40%) 3 (42.9%) .89
High 9 (60%) 4 (57.1%)
Nuclear pAKT Low 7 (46.7%) 1 (14.3%) .10
High 8 (53.3%) 6 (85.7%)
Cytopl. pAKT Low 4 (26.7%) 5 (71.4%) .04
high 11 (73.3%) 2 (28.6%)
pS6RP Low 6 (37.5%) 5 (71.4%) .10
High 10 (62.5%) 2 (28.6%)
P4E-BP1 Low 10 (62.5%) 6 (85.7%) .19
High 6 (37.5%) 1 (14.3%)
Correlations by Fisher's exact test.
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the whole patient cohort.
Patterns of Expression of mTOR Pathway Markers
Representative images of microscopic pictures showing tumor cells
with positive and negative staining for all markers are shown in
Figure 3. Nuclear LKB1 expression was high in 21 cases (65.6%)
(Figure 3A), whereas 11 cases (34.4%) had low expression
(Figure 2C). Cytoplasmic LKB1 expression was high in 20 cases
(62.5%) (Figure 3B), whereas 12 cases (37.5%) showed low
expression.
Nuclear pAKT was high in 20 cases (62.5%) (Figure 3D) and low
in 12 cases (37.5%), whereas cytoplasmic pAKT was high in 22 cases
(68.8%) (Figure 3E) and low in 10 cases (31.2%) (Figure 3F).
Phospho-4EBP1 expression was high in 14 patients (42.4%)
(Figure 3G) and low in 19 patients (57.6%) (Figure 3H). Phospho-S6
ribosomal protein expression was high in 19 patients (57.6%)
(Figure 3I) and low in 14 patients (42.2%) (Figure 3J).
By NGS and among the 24 patients' samples tested for PIK3CA
hotspot mutations, 2 mutations were detected in exon 9 (P539R and
E542K) and 5 mutations were detected in exon 20 (3 mutations in
H1047L, 1 in G1049R, and 1 in R1049G), with a total of 7 patients
who had mutated PIK3CA (29.2%). Four of the patients' samples
could not be sequenced for the target exons despite two experiments
for sequencing. Table 1 shows the expression distribution of the
different biomarkers.
PI3K Hotspot Mutations Were Associated with Nuclear pAKT
Localization but Not with Downstream Activation Markers
The tumors with PIK3CA hotspot mutations had more association
with nuclear localization of pAKT, i.e., increased incidence of high
nuclear pAKT expression (85.7% vs 53.3%; P = .10) and decreased
incidence of high cytoplasmic pAKT expression (28.6% vs 73.3%;
P = .04) compared with PIK3CA nonmutant tumors.
Moreover, there was a tendency toward negative correlation
between PIK3CA mutations and the higher expression of the
downstream substrates of mTOR. For example, in PIK3CA mutant
tumors, pS6RP expression was high in 28.6% of the cases versus62.5% in PIK3CA wild-type tumors (P = .10). Also, p4E-BP1 showed
similar tendency with high expression in only 14.3% of PIK3CA
mutant versus 37.5% in PIK3CA wild-type tumors (P = .19).
No correlation was found between PI3K mutational status and the
expression or the subcellular localization of LKB1. A summary of
correlations between the PI3K mutations by NGS and the protein
expression by IHC of pAKT, pS6RP, LKB1, and p4E-BP1is shown
in Table 2.
Correlations between Expression of the Different Biomarkers
Downstream of the PI3K
High nuclear and cytoplasmic LKB1 expression showed tendency
for correlation with the expression of the phosphorylated forms of the
downstream mTOR substrates: pS6RP and p4E-BP1. For example,
in tumors with high pS6RP levels, 78.9% highly expressed LKB1,
whereas only 21.1% had low LKB1 expression (P = .05).
Also, the higher the pAKT was expressed in both the cytoplasm
and the nuclei, the higher was the expression of the downstream
molecules. Among the 12 tumors with low nuclear pAKT expression,
only 5 tumors had high pS6RP levels versus 14 of 20 tumors with
high nuclear pAKT expression (P = .11). Similarly, among the 12
tumors with low pAKT levels, only 2 patients had high p4E-BP1
expression versus 12 tumors (with high p4EBP1) in the high–pAKT
expression subgroup (P = .01).
Moreover, the expressions of both pS6RP and p4E-BP1 were
correlated together, i.e., expression of one marker predicted the
expression of the other (P = .03). Table 3 summarizes the correlations
between the different biomarkers and their statistical significance.
Nuclear LKB1 Association with Good Prognosis
Patients with tumors that highly express LKB1 in their nuclei were
more likely to be younger than 50 years (P = .06) and premenopausal
(P = .06). Nuclear LKB1 expression was associated with features of
good prognosis such as smaller tumor sizes (P = .05) and more ER
positivity (P = .08), PgR positivity (P = .002), and HER2 negativity
(P = .06).
Cytoplasmic LKB1, on the other hand, was not associated with age
or with ER, PgR, or HER2 status, but its expression was associated
with smaller tumors (P = .03). Table S2 shows a summary of the
correlations between nuclear and cytoplasmic expression of LKB1
with the different clinicopathologic factors.
In the Kaplan-Meier model, the 60-month RFS rate of patients with
high expression of nuclear LKB1 was 76.3% versus 48% in patients
Table 3. Correlations between Expression of pS6RP, p4EBP1, pAKT, and LKB1
Marker pS6RP Low No. (%) pS6RP High No. (%) P Value p4E-BP1 Low No. (%) p4E-BP1 High No. (%) P Value
Nuclear pAKT Low 7 (53.8%) 5 (26.3%) P = .11 10 (55.6%) 2 (14.3%) P = .01
High 6 (46.2%) 14 (73.7%) 8 (44.4%) 12 (85.7%)
Cytopl. pAKT Low 8 (61.5%) 2 (10.5%) P b .01 8 (44.4%) 2 (14.3%) P = .06
High 5 (38.5%) 17 (89.5%) 10 (55.6%) 12 (85.7%)
Nuclear LKB1 Low 7 (53.8%) 4 (21.1%) P = .05 8 (44.4%) 3 (21.4%) P = .17
High 6 (46.2%) 15 (78.9%) 10 (55.6%) 11 (78.6%)
Cytopl. LKB1 Low 8 (61.5%) 4 (21.1%) P = .02 9 (50.0%) 3 (21.4%) P = .09
high 5 (38.5%) 15 (78.9%) 9 (50.0%) 11 (78.6%)
P4E-BP1 Low 11 (78.6%) 8 (42.1%) P = .03
High 3 (21.4%) 11 (57.9%)
Correlations tested by Fisher's exact test.
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LKB1 expression was associated with decreased risk of recurrence or
death (hazard ratio = 0.36; 95% CI, 0.15 to 1.10; P = .08).
However, expression of cytoplasmic LKB1 was not predictive of
the outcome of breast cancer (hazard ratio = 0.81; 95%CI, 0.22 to 3.03;
P = .76). The Kaplan-Meier curves for high versus low expression of
nuclear and cytoplasmic LKB1 are shown in Figure 4, A and B.
Nuclear pAKT Had a Prognostic Significance
Patients with tumors that highly express nuclear pAKT tended to
have more ER and PgR positivity (P = .10 and .15, respectively),
whereas cytoplasmic expression of pAKT was associated with younger
age and more premenopausal women (P = .11) and did not show any
correlation with the different histopathologic factors. Table S3 shows
a summary of the correlations between nuclear and cytoplasmic
expression of pAKT with the different clinicopathologic factors.
In the Kaplan-Meier model, the 60-month RFS rate of patients
with high expression of nuclear pAKT was 70.8% versus 53% in
patients with low expression (P = .12). In the Cox univariate model,
nuclear pAKT expression tended to decrease risk of recurrence or
death (hazard ratio = 0.51; 95% CI, 0.11 to 1.16; P = .13).
However, expression of cytoplasmic pAKT did not predict the
outcome of breast cancer (hazard ratio = 1.11; 95% CI, 0.28 to 4.45;
P = .88). Kaplan-Meier curves for high versus low expression of
nuclear and cytoplasmic pAKT are shown in Figure 4, C and D.
Impact of Downstream Markers Expression
Tumors with high expression of p4E-BP1 and pS6RP were more
likely to occur in patients younger than 50 years (P = .01 and .07,
respectively) and in premenopausal women (P = .01 and .07,
respectively). Such high expression of p4E-BP1 and pS6RP did not
consistently correlate with the tumor stage or with the biological
characteristics of breast cancer such as HR status, HER2 status,
and SBR grade. A summary of these correlations is shown in
Table S4.
Regarding the RFS analysis, neither p4E-BP1 nor pS6RP was a
significant prognostic factor in patients with luminal breast cancer.
For p4E-BP1 high expression, HR for relapse or death was 0.61 (95%
CI, 0.16 to 2.37; P = .48), and for pS6RP high expression, HR for
relapse or death was 1.15 (95% CI, 0.32 to 4.07; P = .83). Figure 4,
E and F, shows the Kaplan-Meier curves for RFS of high versus low
expression of p4E-BP1 and pS6RP.
Discussion
Endocrine therapy is the cornerstone treatment in luminal breast
cancers. Nevertheless, more than 50% of HR-positive patients willescape hormone sensitivity in the adjuvant setting, with subsequent
relapse of their disease, representing a major therapeutic challenge in
such patients. Extensive evidence has implicated PI3K/AKT/mTOR
axis aberrations in the process of secondary endocrinal resistance,
which gave a strong rational for the development of several PI3K
pathways inhibitors in clinical trials. Our study was designed in 2011,
influenced by the impressive results of the mTOR inhibitor
everolimus in prolonging PFS in patients with HR+/HER−
metastatic breast cancer in the context of aromatase inhibitors
resistance. On the other hand, pivotal preclinical studies have strongly
suggested that earlier intervention with combined endocrine and
PI3K-directed therapies could limit escape from endocrine therapy
(ET) during the adjuvant phase of the disease, a hypothesis that is
now being tested in at least two ongoing phase 3 studies. Of note, the
toxicity from this combination is significant, and many patients
treated with this approach during the metastatic settings were
reported to decline treatment as a result of adverse events. Therefore,
it is of prime importance to explore specific tumor biomarkers that
can a priori identify those patients who might benefit from such
effective, albeit toxic, treatment, particularly in the adjuvant setting.
Accordingly, in our study, we tried to characterize some molecular
changes associated with PIK3CAmutation status and their prognostic
relevance in a cohort of ER+/HER2− Egyptian patients with early
breast cancer treated with adjuvant endocrine therapy.
Our study was designed in 2011, influenced by the promising success
of mTOR inhibitors in improving the outcome of metastatic breast
cancer patients, particularly in the aspect of overcoming resistance to
hormonal therapies. The different studies showing high prevalence of
the PI3K/AKT/mTOR axis aberrations in that population, in addition
to the success of the mTOR inhibitor everolimus in the prolongation of
PFS in ER-positive, HER2-negative advanced breast cancer, offered an
open opportunity to explore the potential role of the different
components of the PI3K/AKT/mTOR in the development of hormone
resistance in breast cancer. Such resistance in the adjuvant setting should
manifest by shorter RFS.
In the current report, we detected PIK3CA hotspot mutations in
exons 9 and 20 in 29.2% of the studied population. This is
concordant with what has been reported by others [18–20] including
a single study on a relatively similar ethnicity from Saudia Arabia,
which detected PIK3CA mutations in 32% in a cohort of 50 cases of
luminal breast cancer [21]. Of notice, a higher incidence of PIK3CA
mutations is consistently reported among patients with strong ER and
PR expression status compared with other breast cancer phenotypes.
In a recent study by the Cancer Genome Atlas Network, PIK3CA
mutations were detected in 45% and 29% of luminal A and luminal
B subtypes, respectively [22].
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Figure 4. Kaplan-Meier curves of RFS (months) across different levels of biomarker expression: high (green) versus low (dotted blue)
expression of nuclear and cytoplasmic LKB1, nuclear and cytoplasmic pAKT, p-4E-BP1, and p-S6RP.
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PIK3CA mutations could be responsible for the oncogenic
deregulation in the poor prognosis luminal breast cancers, and
consequently, these patients would be most suitable for treatment by
PI3K/m-TOR pathway inhibitor.
In our analysis, no prognostic impact of the PIK3CA mutational
status was found in our small cohort of luminal breast cancers. Other
larger studies described conflicting results on the prognostic value of
PIK3CA mutational status in this patient population [18,20,23]. The
largest, and probably the most reliable, data set regarding the
prognostic significance of PIK3CA mutations in luminal breast
cancer evolved from a study of 4540 patients with luminal breast
cancers included in the TEAM trial. In this study, PIK3CA mutations
(found in approximately 40% of the cases) were associated with a
significantly better 5-year distant RFS (hazard ratio, 0.76; 95% CI,
0.63 to 0.91; P = .003). However, after adjustment for other clinical
and biological parameters, such favorable prognostic impact did not
remain significant in a multivariate analysis (hazard ratio, 0.92; 95%CI, 0.75 to 1.12; P = .4012) [24]. We think that the TEAM results in
addition to other smaller studies including ours would probably close
the debate on the prognostic value of PI3K mutation, which may
display a limited favorable prognostic impact, but it cannot be
considered a strong independent predictor of outcome in the context
of hormone receptor (HR) positive early breast cancer (EBC). Indeed,
PIK3CA mutations in EBC may serve as a marker of highly
hormone-dependent, relatively indolent tumors in which ER and
PI3K signaling coexists but with a dominant effect of ER
transcription. Of note, PIK3CA mutations in endometrial cancer
were also reported to be associated with a less aggressive phenotype.
In the metastatic settting, a strong preclinical evidence on the
involvment of PI3K/mTOR pathway activation in the development
of acquired (secondary) resistance to hormonal therapy has been well
acknowledged. In the clinic, this was clearly evident by the
therapeutic benefit achieved by the addition of everolimus to
hormonal therapy in two randomized trials [12,13]. However, the
predictive role of PIK3CA mutation on the likelihood to benefit from
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More interiguingly, Loi et al., in a cohort of 58 HR+/HER2−
patients, have shown that patients with gene signature associated to
PIK3CA wild-type—and not PIK3CA mutation—were those who
made a significant therapeutic benefit from everolimus plus letrozole
compared with letrozole alone when given during the neoadjuvant
setting [27]. Taken together, although high hopes were expected from
the presence of PIK3CA mutations to serve as a prognostic and/or
predictive biomarker in HR+/HER− breast cancers, the current
evidence does not indicate a clinically relevant role of PIK3CA
mutations in this cohort of patients. This stands in clear
contradistinction with the situation in HER-positive metastatic
breast cancer where PIK3CA mutations have been shown to be
associated with a significantly worse prognosis and less response to
trastuzumab treatment.
An important result detected in our work is the correlation between
PI3K mutations and the nuclear localization of pAKT which might
indicate its activation. However, this was not correlated with higher
expression of downstream effectors of the mTOR pathway. On the
contrary, PIK3CA mutated cases tended to have lower expression of
pS6RP and p4EBP1 compared with patients with wild-type PIK3CA.
Importantly, an extensive study, including 1800 HR+ breast cancer
patients, trying to link PIK3CA mutation with mTOR pathway
activation (as detected by gene signature) could not demostrate a
positive correlation between the two events. Paradoxically, PIK3CA
mutations in this study were associated with a low mTORC1
signaling gene signature [28]. This underscores the importance of
other alternative pathways responsible for mTOR activation and the
potential role of complex feedback loops regulated signaling of
this pathway.
Regarding the pAKT expression, we found different patterns of
expression of nuclear and cytoplasmic pAKT. No correlation was
found between the nuclear and cytoplasmic expression, denoting
complete independence of both stainings. We might hence conclude
that this molecule has different actions depending on its subcellular
localization. Only nuclear expression of pAKT carried tendency to
predict a longer RFS that did not reach statistical significance because
of the small sample size. This finding is opposite to what is expected
from the role of pAKT in tumor progression and growth from
preclinical studies and several other retrospective analyses [29–32].
However, in the same line with our work, a study conducted by
Badve et al. in 377 breast cancer patients found a better outcome in
patients with nuclear localization of pAKT in ER/PgR-positive
patients [33].
In our work (as with pAKT), high nuclear LKB1 expression
showed a tendency to predict better DFS and was associated with
markers of good prognosis such as smaller tumor size, and ER and
PgR positivity. Such associations were not found with the cytoplasmic
expression. These findings are concordant with what was observed by
Bouchekioua-Bouzaghou and colleagues about the differential
prognostic impact of the subcellular localization of LKB1. In their
study, they described a better outcome with nuclear LKB1 and a
poorer survival with cytoplasmic LKB1 expression [34].
A growing interest in LKB1 expression has increased after the
translational study of TAMRAD showed that patients with low
cytoplasmic LKB1 were more likely to benefit from the addition of
everolimus, and suggested an inverse correlation between cytoplasmic
LKB1 and nuclear p4EBP1. However, in a larger series of breast
cancers (n = 154), the same group demonstrated a positive correlationbetween both markers, which seems to contradict the former results
[34]. In fact, no statistical analysis has been done for such correlation
in the TAMRAD study which aimed at discovering predictive
markers for everolimus response.
We have also studied the expression of the downstream markers of
mTOR activation: pS6RP and p4E-BP1. Both biomarkers’ expres-
sions were correlated, i.e., pS6RP and p4E-BP1 had a high
probability of mutual expression. Neither the high expression of
p4E-BP1 nor that of pS6RP had an impact on the prognosis of breast
cancer patients.
Despite the unclear prognostic impact of the upstream biomarkers,
the downstream molecules (particularly S6K and p4E-Bp1) predicted
poorer outcome of breast cancer in most of the studied series. In a
Swedish study done on more than 700 patients from the Stockholm
tamoxifen studies, high mRNA levels of S6K2 and 4E-BP1 (which
also had strong tendency toward mutual expression) were associated
with poor prognostic factors such as higher grade and larger tumors
and were independent predictors of poor survival. In the same study,
higher 4E-BP1 and p4E-BP1 expression by IHC predicted distant
recurrences and breast cancer mortality [35]. Such notion (of poor
prognostic impact of the downstream markers) is in line with other
retrospective studies [36–38]. Such impact was not observed in our
sample of Egyptian patients probably as a result of small sample size.
Although our work was comprehensive in terms of the spectrum of
biomakers analyzed, their subcellular localization, and their prognos-
tic impact, still it is obviously limited by its retrospective nature, the
use of TMA sections that bear only cores of the whole tumor, and the
heterogeneity of our patient cohort regarding the adjuvant treatment
received that may bias the results. In our opinion, the biggest
limitation is the small size of our sample that makes drawing solid
conclusions very difficult. A larger prospective biomarker-oriented
study powered to account for the various prognostic variables in a
multivariate analysis is needed to further clarify the missing pieces of
the PI3K/AKT/mTOR story.
Finally, this study is throwing lights on the technical difficulties to
conduct this kind of retrospective-prospective studies in developing
countries, where the absence of standardized tumor tissue banks is
still a major problem. The importance of collaborative translational
studies like the one we did in our work will certainly support the idea
of having a high-quality research on different ethnic groups where
breast cancer patients may exhibit a molecularly different profile.
The extreme complexity of the mTOR pathway activation
mechanisms, the multiplicity and redundancy of the interactions
between its components, and the presence of various feedback loops
that control mTOR activation are all responsible for the inconsistent
results of similar studies, and that is why none of those biomarkers
were adopted into clinical practice. What we know so far is that
suppression of the mTOR pathway can improve the outcome in a
subgroup of luminal breast cancer patients, and this means that the
mTOR pathway activation is responsible for tumor progression in
such subgroup. What we also know (from the translational data of the
BOLERO2 and TAMRAD studies) is that a consistent
PIK3CA mutational status is not predictive of benefit from the
mTOR inhibitors.
In conclusion, our work supports the idea of the presence of at least
two pathways for mTOR activation: AKT dependent and AKT
independent. PIK3CA hotspot mutations in exons 9 and 20 are
mostly associated with AKT activation but have little correlation with
the downstream markers such as p4E-BP1 and pS6RP. AKT-
122 PI3K/mTOR Pathway Biomarkers in Breast Cancer Azim et al. Translational Oncology Vol. 9, No. 2, 2016independent mTOR activation, which is associated with wild-type
PIK3CA and high expression of the downstream markers, seems to
define a subgroup of tumors that might be deriving the most benefit
from rapamycin-like mTOR inhibitors. Our findings need further
confirmation in larger validation cohort and longer follow-up to test
for the effects of other prognostic variables.
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